LEADER 05235nam 2200637Ia 450 001 9910144561603321 005 20210223172608.0 010 $a1-281-76404-3 010 $a9786611764043 010 $a3-527-61302-1 010 $a3-527-61303-X 035 $a(CKB)1000000000377124 035 $a(EBL)481814 035 $a(OCoLC)261222514 035 $a(SSID)ssj0000212533 035 $a(PQKBManifestationID)11174885 035 $a(PQKBTitleCode)TC0000212533 035 $a(PQKBWorkID)10138183 035 $a(PQKB)11454388 035 $a(MiAaPQ)EBC481814 035 $a(EXLCZ)991000000000377124 100 $a20001125d2001 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel therapeutic proteins$b[electronic resource] $eselected case studies /$fedited by Klaus Dembowsky and Peter Stadler 210 $aWeinheim ;$aNew York $cWiley-VCH$dc2001 215 $a1 online resource (388 p.) 300 $aDescription based upon print version of record. 311 $a3-527-30270-0 320 $aIncludes bibliographical references and index. 327 $aNovel Therapeutic Proteins; Foreword; Preface; Contents; Introduction and Overview; 1 Medical Applications of Recombinant Proteins in Humans; 1.1 Introduction; 1.2 Presently Approved Biotech Products; 1.3 Biotechnology Products in Clinical Development; 1.4 Specific Diseases and Applications; 1.4.1 Myocardial Infarction and Stroke; 1.4.2 Heart Failure; 1.4.3 Fibrosis; 1.4.4 Osteoporosis; 1.4.5 Obesity, Insulin Resistance, and Non-Insulin Dependent (Type II) Diabetes; 1.4.6 Sepsis; 1.4.7 Immunoenhancement; 1.4.7.1 Tumor Therapy; 1.4.7.2 Vaccines; 1.4.8 Immune Deviation 327 $a1.4.9 Multiple Sclerosis (MS)1.4.10 Psoriasis; 1.4.11 Arthritis; 1.4.12 Inflammatory Bowel Disease; 1.4.13 Allergy and Asthma; 1.4.14 Replacement Therapies; 1.4.15 Viral Infections; 1.4.16 Reproductive Medicine .; 1.4.17 Other; 1.5 Conclusion; 1.6 References; Recombinant Hormones; 2 Clinical Applications of Recombinant Human Erythropoietin; 2.1 Structure of Human Erythropoietin; 2.2 General Principles; 2.3 Medical Applications of Recombinant Human EPO; 2.3.1 The Anemia of Chronic Renal Failure (CRF); 2.3.2 Acquired Immunodeficiency Syndrome (AIDS) 327 $a2.3.3 Chemotherapy Induced Anemia of Non-Hematologic Malignancies 2.3.4 The Perioperative Setting; 2.3.4.1 Recombinant Human EPO without Autologous Blood Donation; 2.3.4.2 Recombinant Human EPO as an Adjunct to Autologous Bood Donation; 2.3.5 The Anemia of Prematurity; 2.3.6 The Anemia of Hematologic Malignancies; 2.3.7 Myelodysplastic Syndromes and Other Hematologic Stem Cell Disorders; 2.3.8 Bone Marrow Transplantation (BMT); 2.3.9 The Hemoglobinopathies; 2.3.10 The Anemia of Chronic Inflammation; 2.4 Patient Response and Medical Economics 327 $a2.5 Pharmacokinetics : Dosage, Routes of Administration. and Effect Monitoring 2.6 Iron Supplementation during rhEPO Treatment; 2.7 Future Directions; 2.8 References; 3 Human Recombinant Growth Hormone; 3.1 Introduction; 3.2 Hypothalamic Regulation; 3.2.1 Somatostatin; 3.2.2 Growth Hormone Releasing Hormone; 3.2.3 Other Neurotransmitters; 3.3 Peripheral Regulation of GH; 3.4 Mechanisms of Action of GH; 3.4.1 GH Receptor; 3.4.2 Metabolic Effects; 3.4.3 Insulin Growth Factors (IGF); 3.4.3.1 Circulation of IGF; 3.4.3.2 Receptors of IGF; 3.4.3.3 Actions of IGF; 3.5 GH Effects on Growth 327 $a3.5.1 Dwarfism 3.5.2 Gigantism; 3.5.3 Acromegaly; 3.5.4 GH Deficiency in the Adult; 3.6 Production of GH; 3.6.1 Preparations Obtained by Extractions; 3.6.2 Genetic Engineering of GH; 3.6.2.1 Synthesis in Prokaryotic Cells; 3.6.2.2 Second Synthetic Procedure for GH Synthesis; 3.6.2.3 Third Synthetic Procedure for GH Synthesis; 3.6.2.4 Synthesis of hGH in Eukaryotic Cells; 3.7 Therapy with GH; 3.7.1 Use of rhGH in the Treatment of GH Defiency; 3.7.2 Use of rhGH in Chronic Renal Failure (CRF); 3.7.3 Use of rhGH in Turner's Syndrome; 3.7.4 Use of GH in Different Catabolic States and in AIDS 327 $a3.8 References 330 $aThis book describes medical applications of recombinant proteins and monoclonal antibodies, some of which have already been on the market for several years while others have only recently been launched. It also highlights the manufacturing processes for individual products, the strategies that were taken by companies in the clinical development, and the hurdles that were encountered in clinical trials and had to be overcome before approval by regulatory authorities. Finally, this book illustrates strategies to modify and improve the pharmacodynamic and pharmacokinetic properties of naturally o 606 $aGene therapy$vCase studies 606 $aRecombinant proteins$vCase studies 608 $aElectronic books. 615 0$aGene therapy 615 0$aRecombinant proteins 676 $a615.3 676 $a660.6 701 $aStadler$b Peter$cDr.$0408042 701 $aDembowsky$b Klaus$0916476 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910144561603321 996 $aNovel therapeutic proteins$92054469 997 $aUNINA